Sort   by:  
 Page size 
UnknownFirst-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Not available
S-EPMC9433959 | biostudies-literature
UnknownTNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.
Not available
S-EPMC12521918 | biostudies-literature
UnknownAcquired Resistance to KRASG12C Inhibition in Cancer.
Not available
S-EPMC8864540 | biostudies-literature
UnknownEfficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Not available
S-EPMC5824288 | biostudies-literature
UnknownBacille Calmette-Guerin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial.
Not available
S-EPMC11106519 | biostudies-literature
UnknownRandomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
Not available
S-EPMC10497190 | biostudies-literature
UnknownBacillus Calmette-Guerin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial.
Not available
S-EPMC10500555 | biostudies-literature
UnknownImpact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Not available
S-EPMC10275699 | biostudies-literature
UnknownReal-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.
Not available
S-EPMC12166372 | biostudies-literature
UnknownSARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Not available
S-EPMC9762734 | biostudies-literature
Sort   by:  
 Page size